WAG disclosure on potential impact of Express Scripts narrow networks
On both the latest ESPX and RAD earnings calls, each CEO was asked by analysts if they knew the extent to which ESPX customers had opted for a narrow network, which will exclude WAG. Both CEOs acknowledged that they did, but deferred the question to WAG management with the RAD CEO citing contractual reasons for the deferral. I understand that Tricare (the DOD) represented 18% of the prescriptions WAG used to process for ESPX and its been reported that other customers have opted for a network that excludes WAG.
Has WAG provided any specific disclosure on the percent (or dollars) of customer revenue lost due to ESPX customers going to narrow networks? I've looked, did I miss it?. If not currently disclosed, I'll be interested to see WAG management's response to this question tomorrow.